Justin Zelin (BTIG) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Justin Zelin's stock ratings?

About 23% of Justin's ratings were profitable over a one-year hold, with an average return of -21.6% per rating, measured by 13Foresight from historical prices.

Q: How is Justin ranked?

Justin Zelin is ranked #2563 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Justin Zelin

BTIG

Justin Zelin

BTIG

Wall Street Analyst

★☆☆☆☆

#2563

on 13Foresight · ranked by our own returns

23%

Success Rate

-21.6%

Average Return

6 of 26 calls profitable · -37.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 23% of Justin Zelin's ratings turned a profit when each position was held for 1 year — averaging -21.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

50 Buy 8 Hold 0 Sell

Justin's Stock Coverage 30 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
IBRX ImmunityBio	Feb 02, 2026	BUY	Strong Buy +52.6% avg upside 12 analysts	$9.00 22.26% Upside	+30.0%
JANX Janux Therapeutics Inc	Jan 22, 2026	BUY	Strong Buy +217.1% avg upside 21 analysts	$100.00 603.22% Upside	-6.5%
NBP NovaBridge Biosciences	Jan 06, 2026	BUY	Strong Buy +1309.7% avg upside 14 analysts	$9.00 499.95% Upside	·
AVBP ArriVent BioPharma, Inc.	Jan 02, 2026	BUY	Strong Buy +37.0% avg upside 15 analysts	$45.00 41.82% Upside	+50.8%
SNDX Syndax Pharmaceuticals	Jan 02, 2026	BUY	Strong Buy +88.8% avg upside 27 analysts	$56.00 194.68% Upside	-14.0%
KURA Kura Oncology	Dec 09, 2025	HOLD	Strong Buy +161.3% avg upside 26 analysts	—	-10.3%
TCRX TScan Therapeutics	Dec 09, 2025	HOLD	Strong Buy +823.9% avg upside 12 analysts	—	-11.3%
AAPG Ascentage Pharma Group International Unsponsored ADR	Dec 02, 2025	BUY	Strong Buy +156.7% avg upside 10 analysts	$50.00 192.10% Upside	-35.2%
JSPR Jasper Therapeutics	Dec 02, 2025	BUY	Strong Buy +6361.2% avg upside 17 analysts	$7.00 1445.34% Upside	-70.2%
BCAB BioAtla	Nov 14, 2025	BUY	Strong Buy +2518.3% avg upside 13 analysts	$500.00 13579.79% Upside	-89.2%
LYRA Lyra Therapeutics	Nov 13, 2025	HOLD	Hold +3282.4% avg upside 7 analysts	—	-80.4%
VSTM Verastem	Nov 04, 2025	BUY	Strong Buy +260.2% avg upside 23 analysts	$20.00 385.46% Upside	-49.4%
IDYA IDEAYA Biosciences	Nov 04, 2025	BUY	Strong Buy +55.2% avg upside 29 analysts	$62.00 98.58% Upside	+2.6%
VKTX Viking Therapeutics	Oct 30, 2025	BUY	Strong Buy +141.1% avg upside 30 analysts	$125.00 311.41% Upside	-22.3%
IPHA Innate Pharma	Sep 17, 2025	BUY	Strong Buy +261.8% avg upside 10 analysts	$8.00 341.94% Upside	-1.5%
ELVN Enliven Therapeutics	Aug 14, 2025	BUY	Strong Buy +7.1% avg upside 14 analysts	$45.00 0.32% Downside	+119.8%
LEGN Legend Biotech	Aug 11, 2025	BUY	Strong Buy +140.3% avg upside 27 analysts	$91.00 225.76% Upside	-1.0%
IMCR Immunocore Holdings	Mar 11, 2025	BUY	Strong Buy +124.3% avg upside 22 analysts	$91.00 218.20% Upside	+14.4%
CARM Carisma Therapeutics	Jan 14, 2025	HOLD	Buy +15294.7% avg upside 11 analysts	—	-90.8%
ACET Adicet Bio	Sep 10, 2024	BUY	Strong Buy +212.8% avg upside 14 analysts	$6.00 25.84% Downside	-43.9%
PROK ProKidney	Sep 03, 2024	BUY	Buy +260.7% avg upside 12 analysts	$5.00 173.17% Upside	-1.7%
DTIL Precision BioSciences	May 13, 2024	BUY	Strong Buy +247.1% avg upside 12 analysts	$30.00 340.58% Upside	-55.3%
MBIO Mustang Bio	Mar 12, 2024	BUY	Strong Buy +938.4% avg upside 5 analysts	$8.00 1130.74% Upside	-97.3%
CASIF CASI Pharmaceuticals	May 05, 2023	HOLD	Strong Buy +14376.2% avg upside 5 analysts	—	·
LITS Lite Strategy	May 05, 2023	HOLD	Buy +1215.4% avg upside 13 analysts	—	·
SNGX Soligenix	Dec 04, 2020	BUY	Buy +726.0% avg upside 6 analysts	$4.00 901.32% Upside	-68.0%
SCPX Scorpius Holdings	Nov 11, 2020	BUY	Strong Buy +1664672.8% avg upside 11 analysts	$28.00 2545354.59% Upside	·
KRYS Krystal Biotech	Nov 11, 2020	BUY	Strong Buy -28.3% avg upside 19 analysts	$100.00 71.33% Downside	+17.7%
ABEO Abeona Therapeutics	Nov 11, 2020	BUY	Strong Buy +195.8% avg upside 17 analysts	$3.00 47.93% Downside	-27.7%
GERN Geron	Nov 11, 2020	BUY	Strong Buy +239.8% avg upside 19 analysts	$4.00 217.45% Upside	-20.3%

🔒 25 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Justin Zelin — Frequently Asked Questions

How accurate are Justin Zelin's stock ratings?

Based on the calls 13Foresight could measure, about 23% of Justin's ratings were profitable over a one-year hold, with an average return of -21.6% per rating, or -37.2% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Justin ranked on 13Foresight?

Justin Zelin is currently ranked #2563 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Justin cover?

Justin most recently has ratings on IBRX, JANX, NBP, AVBP, SNDX, KURA, TCRX, AAPG, JSPR, BCAB, LYRA, VSTM and 18 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!